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Background: Clinical complications appear to be a decisive factor for the prognosis of patients. Diabetes is an
important complication of cystic fibrosis(CF). In our study we evaluated the association between the IVS4G>T
mutation in the TCF7L2 gene with the presence of diabetes in patients with CF.
Findings: We evaluated 145 patients with CF in relation to the genotype of the IVS4G>T mutation. For this, the
PCR method associated with specific enzyme digestion was used. The genotypes G/G, G/T and T/T were observed
to have frequencies of 54 (37.2%), 78 (53.8%) and 13 (9%), respectively. There was no association between genotype
and the occurrence of diabetes among patients.
Conclusions: In our sample, no association was found between the IVS4G>T mutation in the TCF7L2 gene and
diabetes.
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Introduction
Cystic Fibrosis (CF) is a monogenic autosomal recessive
disease more common in the Caucasian population. It
has the overall prevalence of 1:2500 births [1].
CF occurs due to mutations in the gene CFTR (“Cystic
Fibrosis Transmembrane Conductance Regulator”)
located in the 7q3.1 region, which encodes the CFTR
protein. Over 1897 mutations were identified in the
CFTR gene [2].
The disease is characterized by a higher viscosity of
secretions leading to chronic obstructive pulmonary dis-
ease, recurrent respiratory tract infections, pancreatic in-
sufficiency, increased concentration of chloride in sweat
and male infertility [1].
The clinical features of CF are characterized by clinical
heterogeneity; some individuals have early death, while* Correspondence: bertuzzo@unicamp.br
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reproduction in any medium, provided the orothers survive to adulthood [3]. Clinical complications
appear to be a decisive factor for the prognosis of
patients. Diabetes is an important complication of CF.
Diabetes risk increases with age, affecting about 25% of
adolescents and 40–50% of adults with CF [4-6]. As
CF’s patients are now living longer, diabetes has become
the most common systemic complication of CF after
lung disease. Diabetes is associated with a significantly
worse CF prognosis [6,7], although treatment of dia-
betes improves nutritional status and pulmonary func-
tion [8]. Among CF’s patients, the prevalence of
diabetes is approximately tenfold greater (at about one-
third the age) than is seen for type 2 diabetes in the
general population [6,9].
Grant et al. [10] reported on the association of a com-
mon microsatellite (DG10S478) within intron 3 of the
transcription factor 7–like 2 gene (TCF7L2) with type 2
diabetes in an Icelandic case–control sample and repli-
cated this result in two additional case–control cohorts
of white patients. The noncoding single-nucleotide poly-
morphisms rs12255372 and rs7903146 were in strong
linkage disequilibrium with DG10S478 (r2 = 0.95 andLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Association IVS4G>T mutation with clinical
variables in cystic fibrosis patients followed at the
Pediatric Clinic at UNICAMP distribution without the
mutations in the CFTR gene
Sex Male Female Chi-square p-value
G/G 28 (51.9%) 26 (48.1%) 0.144 0.93
G/T 39 (50%) 39 (50%)
T/T 7 (53.8%) 6 (46.2%)
Diabetes No Yes
G/G 39 (72.2%) 15 (27.8%) 3.018 0.221
G/T 64 (84.2%) 12 (15.8%)
T/T 11 (84.6%) 2 (15.4%)
Meconium ileus No Yes
G/G 47 (87%) 7 (13%) 1.014 0.602
G/T 64 (82.1%) 14 (17.0%)
T/T 10 (76.9%) 3 (23.1%)
Age ≤ 154 months > 154 months
G/G 28 (51.9%) 26 (48.1%) 2.141 0.343
G/T 37 (47.4%) 41 (52.6%)
T/T 9 (69.2%) 4 (30.8%)
Table 2 Association IVS4G>T mutation in TCF7L2 gene
after genotypic groupings with clinical variables in cystic
fibrosis patients followed at the Pediatric Clinic at
UNICAMP distribution without the mutations in the CFTR
gene
Sex Male Female Chi-square p-value
G/G 26 (48.1%) 28 (51.9%) 0.078 0.864
G/T and T/T 46 (50.5%) 45 (49.5%)
Diabetes No Yes
G/G 39 (72.2%) 15 (27.8%) 3.017 0.091
G/T and T/T 75 (84.3%) 14 (15.7%)
Meconium ileus No Yes
G/G 47 (87%) 7 (13%) 0.802 0.489
G/T and T/T 74 (83.4%) 7 (18.7%)
Age ≤ 154 months > 154 months
G/G 28 (51.9%) 26 (48.1%) 0.23 1
G/T and T/T 46 (50.5%) 45 (49.5%)
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ciations with type 2 diabetes. The authors recommended
that these two single-nucleotide polymorphisms be gen-
otyped in all attempts at replication [11].
In our study we evaluated the association of the
rs12255372 polymorphism (IVS4G>T mutation) in
TCF7L2 gene with the presence of diabetes in patients
with CF.
Results
This study was approved by the Ethics Committee of the
Faculty of Medical Sciences of University of Campinas -
UNICAMP (#528/2008).
The study included 145 patients with CF who are
monitored by the Pediatric Pulmonology Outpatient
Clinic at UNICAMP.
The genotypes G/G, G/T and T/T were observed with
frequencies of 54 (37.2%), 78 (53.8%) and 13 (9%), re-
spectively. The frequency of G allele was 0.64 and the T
allele 0.36.
Of the total patients, 72 patients (49.7%) were female
and 73 (50.3%) were male, diabetes mellitus was
reported in 29 (20.3%) patients and 114 (79.7%) had no
comorbidity; meconium ileus was diagnosed in 24
patients (16.6%) and 121 (83.4%) had no comorbidity.
The ethnicity of the patients was respectively, 136
(93.8%), 5 (3.4%) and 4 (2.8%) of Caucasoid, Negroid
and mixed race.
For the sample that was screened for the F508del mu-
tation, its frequency was: 37 (25.5%) F508del/F508del, 60
(41.4%) with one F508del allele and 48 (33.1%) patients
without the F508del mutation identified.
74 patients (51%) were aged less or equal than 154
months and 71 patients (49%) greater than 154 months.
Association between genotype of the IVS4G >T muta-
tion and the development of diabetes and the presence
of meconium ileus (Tables 1, 2) was not found. When
the variable presence of the F508del mutation was intro-
duced, an association was still not found in our sample
(Tables 3,4).
Discussion
Florez et al. (2006) [11], examined whether the two most
strongly associated variants (rs12255372 and rs7903146)
predict the progression to diabetes in 3.548 persons with
impaired glucose tolerance who were enrolled in the
Diabetes Prevention Program, in which lifestyle inter-
vention or treatment with metformin was compared
with placebo. The data found showed that the risk alleles
in rs7903146 and rs12255372 predict the risk of diabetes
prospectively, beyond that conferred by the clinical risk
factors.
In 2009, Blackman et al., [6] had already tested
whether a family history of type 2 diabetes affecteddiabetes risk in CF patients in 539 families in the CF
Twin and Sibling family-based study. 998 patients were
evaluated from the family-based study and 802 unrelated
CF patients in an independent case–control study. Fam-
ily history of type 2 diabetes was shown to increase the
risk of diabetes in CF (OR 3.1; p = 0.0009). A variant in
TCF7L2 associated with type 2 diabetes (the T allele at
rs7903146) was associated with diabetes in CF in the
family study (p = 0.004) and in the case–control study
(p = 0.02; combined p = 0.0002). In the family-based
Table 3 Association IVS4G>T mutation in TCF7L2 gene, distributed by genotype for the mutation in the CFTR gene
delF508 with clinical variables in cystic fibrosis patients followed at the Pediatric Clinic at UNICAMP with the
distribution by mutations in the CFTR gene
F508del Sex Male Female Chi-square p-value
-/- G/G 8 (53.3%) 7 (46.7%) 0.756 0.685
G/T 12 (42.9%) 16 (57.1%)
T/T 3 (60%) 2 (40%)
F508del/- G/G 13 (48.1%) 14 (51.9%) 0.932 0.627
G/T 17 (60.7%) 11 (39.3%)
T/T 3 (60%) 2 (40%)
F508del/F508del G/G 5 (41.7%) 7 (58.3%) 0.176 0.916
G/T 1 (33.3%) 2 (66.7%)
T/T 16 (43.2%) 21 (56.8%)
F508del Diabetes No Yes
-/- G/G 12 (80%) 3 (20%) 1.356 0.508
G/T 21 (77.8%) 6 (22.2%)
T/T 5 (100%) -
F508del/- G/G 19 (70.4%) 8 (29.6%) 2.858 0.24
G/T 24 (88.9%) 3 (11.1%)
T/T 4 (80%) 1 (20%)
F508del/F508del G/G 8 (66.7%) 4 (33.3%) 2.042 0.36
G/T 18 (86.4%) 3 (13.6%)
T/T 29 (78.4%) 8 (21.6%)
F508del meconium ileus No Yes
-/- G/G 15 (100%) - 2.286 0.319
G/T 25 (89.35) 3 (10.7%)
T/T 5 (100%) -
F508del/- G/G 22 (81.5%) 5 (18.5%) 0.073 0.964
G/T 22 (78.6%) 6 (21.4%)
T/T 4 (80%) 1 (20%)
F508del/F508del G/G 10 (83.3%) 2 (16.7%) 3.335 0.189
G/T 17 (77.3%) 5 (22.75)
T/T 1 (33.3%) 2 (66.7%)
F508del Age ≤ 154 months > 154 months
-/- G/G 4 (26.7%) 11 (73.3%) 0.813 0.666
G/T 6 (21.4%) 22 (78.6%)
T/T 2 (40%) 3 (60%)
F508del/- G/G 15 (55.6%) 12 (44.45) 2.641 0.267
G/T 12 (42.9%) 16 (57.1%)
T/T 4 (80%) 1 (20%)
F508del/F508del G/G 9 (75%) 3 (25%) 1.37 0.504
G/T 19 (86.4%) 3 (13.6)
T/T 3 (100%) -
(-) absence of F508del mutation.
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Table 4 Association IVS4G>T mutation in TCF7L2 gene after genotypic groupings, distributed by genotype for the
mutation in the CFTR gene delF508 with clinical variables in cystic fibrosis patients followed at the Pediatric Clinic at
UNICAMP with the distribution by mutations in the CFTR gene
F508del Sex Male Female Chi-square p-value
-/- G/G 8 (53.3%) 7 (46.7%) 0.257 0.613
G/T and T/T 15 (45.5%) 18 (54.5%)
F508del/- G/G 13 (48.1%) 14 (51.9%) 0.931 0.335
G/T and T/T 20 (60.6%) 13 (39.4%)
F508del/F508del G/G 5 (41.7%) 7 (58.3%) 0.018 0.893
G/T and T/T 11 (44%) 14 (54%)
F508del Diabetes No Yes
-/- G/G 12 (80%) 3 (20%) 0.01 0.919
G/T and T/T 26 (81.3%) 6 (18.8%)
F508del/- G/G 19 (70.4%) 8 (29.6%) 2.652 0.103
G/T and T/T 28 (87.5%) 4 (12.5%)
F508del/F508del G/G 8 (66.7%) 4 (33.3%) 1.437 0.231
G/T and T/T 21 (84%) 4 (16%)
F508del Meconium ileus No Yes
-/- G/G 15 (100%) - 1.455 0.228
G/T and T/T 30 (90.9%) 3 (9.1%)
F508del/- G/G 22 (81.5%) 5 (18.5%) 0.067 0.795
G/T and T/T 26 (78.8%) 7 (21.2%)
F508del/F508del G/G 10 (83.3%) 2 (16.7%) 0.566 0.452
G/T and T/T 18 (72%) 7 (28%)
F508del Age ≤ 154 months > 154 months
-/- G/G 4 (26.7%) 11 (73.3%) 0.032 0.857
G/T and T/T 8 (24.2%) 25 (75.8%)
F508del/- G/G 15 (55.6%) 12 (44.4%) 0.297 0.586
G/T and T/T 16 (48.5%) 17 (51.5%)
F508del/F508del G/G 9 (75%) 3 (25%) 1.009 0.315
G/T and T/T 22 (88%) 3 (12%)
(-) absence of F508del mutation.
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diabetes about threefold (HR 1.75 per allele, 95% CI 1.3–
2.4; p = 0.0006), and decreased the mean age at diabetes
diagnosis by 7 years. In CF patients not treated with sys-
temic glucocorticoids, the effect of TCF7L2 was even
greater (HR 2.9 per allele, 95% CI 1.7–4.9, p = 0.00011).
A genetic variant conferring risk for type 2 diabetes in
the general population is a modifier of risk for diabetes
in CF.
Given these results, it became interesting to evaluate
the other polymorphism, rs12255372 that is also related
to a risk of diabetes among CF’s patients. Our analysis,
however, found no such correlation.
The absence of a relationship may be due to the sam-
ple size, but since this correlation is of great importance,
it should have appeared even in a small sample. In any
case, with an analysis of a larger number of patients it ispossible that a relationship between the studied poly-
morphism and CF risk can still be evidenced.
Patients and methods
Patients were included in the study from the Pediatric
Clinic at the Faculty of Medical Sciences of UNICAMP.
The sample size calculation was performed by
G-POWER program version 3.1 (using 0.05 alpha, 0.8
beta and W size effect of 0.3). To have the statically
power to all analyses using chi square test we need a
population size of 143 patients. All patients were con-
firmed as having CF through two positive sodium and
chloride sweat tests (value greater than 60 mmol/L) and
by analysis of differential membrane epithelium of the
intestine by the dosage of active CFTR through the
Ussing chamber. The identification of mutations in the
CFTR gene was performed in the laboratory of
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routine analysis tests for major mutations found in the
population of Brazil, which are: F508del, G542X,
R1162X, N1303K, G551D and N1303K. Of the patients
initially included in the survey, only those without clin-
ical data for statistical analysis and/or those who did not
sign the informed consent were excluded.
The DNA was obtained by the extraction technique of
phenol chloroform from 8 mL of venous blood. The
concentration of DNA used for analysis was 50 ng/mL.
Genotyping was performed using the PCR technique
associated with specific enzyme digestion.
The PCR reaction had a 25μL final volume with 100ng
of DNA, 1μM of each primers, 200mM deoxynucleotide
triphosphates, 1.3mM MgCl2, 50mM KCl, 10mM Tris -
HCl (pH 8.4 at 25°C), 0.1% Triton X-100 and 0.35 U Taq
DNA polymerase. A pair of primers were designed and
optimized to amplify the region of the mutation IVS4G>
T, resulting in amplification of 337 bp (S, 50-
CTGGAAACTAAGGCGTGAGG-30, AS, 50-TTGTTGA-
GCTTTACTGAGAT-30). The procedure for the thermal
cycling consisted of initial denaturation at 94°C for 7
min, subsequent denaturation at 94°C for 300, annealing
at 56°C for 450, and extension at 72°C for 2 min,
repeated for 35 cycles, followed by a final extension at
72°C for 7 min.
The product from the PCR had a size of 337 bp and
after digestion by the restriction enzyme Tsp509I, frag-
ments of 143 bp + 99 + 95 - G/G genotype, fragments of
126 + 17 + 99 + 95 bp - T/T genotype and fragments of
143 + 126 + 99 + 95 + 17 bp - genotype G/T were found.
Statistical analysis was performed using the Statistical
Package for Social Sciences (SPSS) v.17.0 and Open Epi
v.5.0 program. Data was compared by different tests
according to data distribution. Initially, data was com-
pared the chi square and Fisher exact test. For all the
analyses we adopted the value of p = 0.05.
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